Carlsmed Reports 58% Q1 Revenue Growth and Raises Full-Year Guidance
CARL is trading near its 52-week low of $8.5 (9.2% above the low).
Summary
Carlsmed reported strong Q1 2026 revenue growth of 58.2% to $16.1 million, improved gross margins, and raised its full-year revenue guidance, signaling robust performance and increased confidence.
Key Events · Earnings and Guidance · CARL
-
Strong Q1 Revenue Growth
Carlsmed reported first-quarter 2026 revenue of $16.1 million, a 58.2% increase compared to $10.2 million in the prior year period.
-
Raised Full-Year Revenue Guidance
The company raised its full-year 2026 revenue guidance to a range of $72 million to $77 million, up from the previous guidance of $70 million to $75 million.
-
Improved Gross Margin
Gross profit for Q1 2026 was $12.4 million, with gross margin improving to 77.1% from 74.9% in Q1 2025.
-
Positive Clinical and Product Milestones
A study published in Global Spine Journal demonstrated a 74% reduction in reoperations for aprevo® personalized lumbar implants. The company also performed the first procedures using the corra™ personalized cervical plating system and aprevo® bi-lateral posterior.
Analysis · CARL · Industrial Applications And Services
Carlsmed, Inc. delivered strong first-quarter results, significantly exceeding prior year revenue and raising its full-year guidance. The 58.2% year-over-year revenue growth to $16.1 million, coupled with an improved gross margin of 77.1%, indicates robust operational performance and increasing adoption of its personalized spine surgery solutions. The decision to raise full-year 2026 revenue guidance to $72-$77 million (from $70-$75 million) signals management's increased confidence in continued growth, driven by recent product milestones and positive clinical data. While net loss increased due to higher operating expenses, this is typical for a growth-focused medical technology company investing in research, development, and market expansion. The positive clinical data for aprevo® and the launch of new products further strengthen the company's market position.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36% of the 1040 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CARL was trading at $9.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $242.9M. The 52-week trading range was $8.50 to $17.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.